SABRE: A New Era for Osteoporosis Trials
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!
The lads sit down with Mary Bouxsein to explore SABRE — the landmark project aiming to make BMD a validated regulatory endpoint in osteoporosis trials. Mary walks us through how her team brought together data from more than 160,000 patients, why this could transform the speed and ethics of future drug development, and what it means for equity and patient care. A big conversation with one of the true leaders in the field — and a glimpse into a future where better treatments reach people…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.